Printer Friendly

PERRIGO RECEIVES FDA APPROVAL TO MARKET LOPERAMIDE HYDROCHLORIDE CAPLET

PERRIGO RECEIVES FDA APPROVAL TO MARKET LOPERAMIDE HYDROCHLORIDE CAPLET
 ALLEGAN, Mich., Nov. 3 /PRNewswire/ -- The Perrigo Company (NASDAQ-NMS: PRGO) announced today that it has been given approval by the Food and Drug Administration (FDA) to manufacture and market Loperamide Hydrochloride Caplet to the store brand market. Loperamide Hydrochloride Caplet is an over-the-counter drug indicated for the control and symptomatic relief of acute, non-specific diarrhea.
 Loperamide Hydrochloride Caplet is comparable to the nationally advertised brand Imodium AD(R) Caplet. Perrigo believes it is the first company to receive approval for this new store brand product through the FDA's Abbreviated New Drug Application (ANDA) process. Importantly, Loperamide Hydrochloride Caplet complements Perrigo's recently announced Loperamide Hydrochloride Liquid, which was approved by the FDA in January 1992 and marketed since March 1992. The company believes the market for Loperamide in caplet form is larger than the market for Loperamide in liquid form.
 Perrigo will begin national distribution of Loperamide Hydrochloride Caplet to retailers and wholesalers in January 1993. Perrigo remains committed to developing new store brand products and its strategy of being among the first companies to manufacture and market certain store brand products, especially in the important health care segment of prescription products switching to over-the-counter status.
 Perrigo Company is the nation's largest manufacturer of over-the- counter (non-prescription) pharmaceuticals and personal care products for the store brand market. Store brand products are sold under a retailer's own label and compete with nationally advertised brand name products. The company's customers are major national and regional drugstore, supermarket and mass merchandise chains and major wholesalers. The company's products include over-the-counter pharmaceuticals (such as analgesics, cough and cold remedies, antacids, laxatives, suppositories, and diet products), personal care products (such as toothpaste and mouthwash, hair care products, deodorants and antiperspirants, baby care products, and skin care and sun care products) and vitamins.
 -0- 11/3/92
 /CONTACT: Thomas J. Ross, director of Investor Relations, Perrigo Company, 616-673-9125/
 (PRGO) CO: Perrigo Company ST: Michigan IN: MTC HEA SU: PDT


JG -- DE014 -- 2216 11/03/92 17:17 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 3, 1992
Words:340
Previous Article:STANDARD & POOR'S STOCK PRICE INDEX -- CLOSING, TUESDAY, NOV. 3
Next Article:EBP ANNOUNCES FILING A SHAREHOLDER SHELF REGISTRATION STATEMENT FOR A SECONDARY OFFERING OF COMMON STOCK
Topics:


Related Articles
PERRIGO RECEIVES FDA APPROVAL TO MARKET LOPERAMIDE HYDROCHLORIDE LIQUID
PERRIGO RECEIVES FDA APPROVAL TO MARKET LOPERAMIDE HYDROCHLORIDE LIQUID
PERRIGO COMPANY REPORTS RECORD QUARTER OF SALES AND EARNINGS
A.L. LABORATORIES ANNOUNCES FDA APPROVAL FOR LOPERAMIDE CAPLETS
ROYCE LABORATORIES, INC. RECEIVES FDA APPROVALS FOR HYDROXYZINE HYDROCLORIDE
AKORN RECEIVES SECOND ANDA APPROVAL REPRESENTING NEW PRODUCT OPPORTUNITY

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters